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Abstract
TWIST is a basic helix–loop–helix (bHLH) transcrip-
tion factor that regulates mesodermal development,
promotes tumor cell metastasis, and, in response to
cytotoxic stress, enhances cell survival. Our screen for
bHLH gene expression in rat C6 glioma revealed TWIST.
To delineate a possible oncogenic role for TWIST in
the human central nervous system (CNS), we analyzed
TWIST message and protein expression in gliomas and
normal brain. TWIST was detected in the large majority
of human glioma–derived cell lines and human gliomas
examined. Increased TWIST mRNA levels were asso-
ciated with the highest grade gliomas, and increased
TWIST expression accompanied transition from low
grade to high grade in vivo, suggesting a role for TWIST
in promoting malignant progression. In accord, elevated
TWIST mRNA abundance preceded the spontaneous
malignant transformation of cultured mouse astro-
cytes hemizygous for p53. Overexpression of TWIST
protein in a human glioma cell line significantly en-
hanced tumor cell invasion, a hallmark of high-grade
gliomas. These findings support roles for TWIST both
in early glial tumorigenesis and subsequent malignant
progression. TWIST was also expressed in embryonic
and fetal human brain, and in neurons, but not glia, of
mature brain, indicating that, in gliomas, TWIST may
promote the functions also critical for CNS development
or normal neuronal physiology.
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Introduction
The basic helix– loop–helix (bHLH) family of proteins regu-
lates normal development and differentiation by forming
DNA-binding heterodimers composed of tissue-specific
(class B) and ubiquitously expressed (class A) proteins that
direct cell-specific gene expression [1,2]. The class B bHLH
protein, TWIST, plays a central role in determining cell fate
in mesoderm, primarily during myogenesis [3–6]. For ex-
ample, TWIST prevents development in normal skeletal
muscle by forming inactive heterodimers with other myo-
genic bHLH proteins (e.g., MyoD and myogenin) that direct the
acquisition of a quiescent, differentiated phenotype [7–9].
TWIST also inhibits the induction of p53-mediated apoptosis
in rodent fibroblasts in response to genotoxins and prolonged
serum deprivation [10]. Both functions of TWIST are likely es-
sential for normal development as evidenced by death in utero
at embryonic day 11.5 in TWIST null mice accompanied by a
high frequency of apoptotic cells [3].
The antiapoptotic function of TWIST suggests that it could
function as an oncogene [10]. In accord, elevated levels of
TWIST mRNA have been observed in the mesenchymal
tumors, rhabdomyosarcoma and osteosarcoma [10,11]. The
recent demonstration of oncogenic cooperation between
TWIST and N-myc amplification in neuroblastoma [12] and
TWIST expression in a variety of carcinomas [11,13,14] sup-
ports an oncogenic function that is not limited to mesenchymal-
derived neoplasms. TWIST expression in gastric carcinoma
[13] has been associated with the initial phase of the metastatic
process whereby tumor cells transition from an epithelial to an
invasive mesenchymal phenotype. Indeed, in a mouse breast
carcinoma model, TWIST is necessary for cells to metastasize
by promoting this epithelial mesenchymal transition (EMT) and
inducing cell motility [15]. Notably, elevated levels of TWIST
mRNA correlate with invasive breast cancer phenotype [15].
Thus, TWIST promotes increased tumor cell survival and
motility—two features characteristic of malignant gliomas. To
our knowledge, TWIST expression has not been characterized
in human primary brain tumors.
Human adult gliomas arise from mature glia and/or glial
progenitors in the brain [16]. Classified histologically in order
of increasing malignancy from grades II to IV, gliomas can
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develop de novo as grade IV neoplasms (glioblastoma multi-
forme) or can undergo malignant progression from low-
grade (grade II) or anaplastic gliomas (grade III) to ‘‘secondary’’
glioblastomas [17,18]. Importantly, as tumors increase in
grade, they also demonstrate enhanced cell survival accom-
panying loss of apoptosis in response to cytotoxic insult, in-
creased tumor cell migration and invasiveness, increased cell
proliferation, and induction of tumor angiogenesis [19–21].
As noted above, in other cell types or cancers, the regulation
of many hallmark behaviors of gliomas has been attributed
to TWIST.
Here we examine TWIST mRNA and protein expression
in human glioma–derived cell lines, glioma tissues, and nor-
mal developing and mature brains, and also in an in vitro
model of glial tumorigenesis using mouse p53-deficient
astrocytes [22–24] to further characterize possible asso-
ciations with gliomagenesis or glial tumor progression. We
also examine the contribution of TWIST to the phenotype
of human glioma cells by analyzing the effect of TWIST
overexpression on invasion in a glioma cell line. Our data
support functions for TWIST that contribute to glial tumori-
genesis and glioma tumor cell behavior, as well as potential
roles in the developing and mature human central nervous
system (CNS).
Materials and Methods
Cell Lines and Tissues
Cell lines studied were derived from glioblastoma (C6,
SNB19, UW18, UW455, UW456, UW467, U87, U138MG,
U373MG, SF763, SF767, A172, and T98G), neuroblastoma
(SKNMC and IMR32), medulloblastoma (D283), and colo-
rectal (SW480 and HT29), breast (MDA231 and MDA453),
and small cell lung cancer (SCLC; H82 and H209). Lines with
the UW designation were established in the authors’ labo-
ratories and grown in DMEM/F12 with 10% fetal bovine
serum (FBS). The remaining cell lines were either obtained
from the Brain Tumor Research Center Tissue Bank (SF767
and SF763; Department of Neurological Surgery, University
of California, San Francisco, CA) or purchased from the
American Type Culture Collection (ATCC; Manassas, VA),
and were cultured as recommended. All human tissues were
obtained in accordance with human subjects protocols ap-
proved by the University of Washington Institutional Review
Board. Tumor and normal brain specimens were obtained
with informed consent from adult patients operated for
glioma, and epilepsy or benign nonglial tumors, respectively.
Clinical and demographic data including pathologic diag-
nosis and tumor grade (based on clinical neuropathology
reports), recurrence status, and prior therapy were noted for
each patient. Adult samples were snap-frozen in liquid
nitrogen and stored at 80jC. At the time of RNA extraction,
a portion of each sample was cut and processed for hema-
toxylin and eosin (H&E) histology. Fetal tissues, obtained
from the University of Washington Birth Defects Research
Laboratory, Department of Pediatrics (Seattle, WA), were ex-
amined and carefully dissected to include only CNS tissues.
Degenerate Reverse Transcription Polymerase Chain
Reaction (RT-PCR) Cloning
Degenerate RT-PCR cloning was utilized to identify novel
class B bHLH genes expressed in the rat C6 glioma cell line.
The design of the degenerate primers was based on con-
served class B–specific sequences within the bHLH region
as previously described [25]. PCR products were cloned into
pCR2.1-TOPO vector with the TOPO-TA system according
to the manufacturer’s instructions (Invitrogen, Carlsbad, CA),
and individual clones were sequenced to identify bHLH
genes. A probe generated from the insert of the TWIST
clone was used for Northern blot confirmation of TWIST
expression in the C6 glioma cell line according to methods
described below.
Northern Blot Analysis
Twenty microgram of total RNA was analyzed for steady-
state levels of TWIST mRNA by Northern blot analysis using
previously published methods [26]. TWIST probe was gen-
erated from a cloned 556-bp fragment from the 3V end of the
gene using the Megaprime DNA labeling system (Amersham
Pharmacia, Piscataway, NJ) with 32P-labeled dCTP. Images
of ethidium-stained 18S and 28S RNA bands were obtained
before and after transfer to confirm loading, RNA integrity,
and complete transfer.
TWIST Expression Constructs and Cell Transfection
The human TWIST cDNA clone (GenBank ID BC036704)
was purchased from ATCC. Open reading frame (ORF) was
amplified with PCR primers: 5V-cgccaccatgatgcaggacgtgtc-
cagctcg-3V and 5V-actagtgggacgcggacatggaccag-3V. The up-
stream primer was designed with Kozak sequence [27] for
improved protein translation. The resulting PCR product
was subcloned into pCR2.1-TOPO vector (Invitrogen) and
verified by sequencing. The EcoRI fragment was then sub-
cloned into the EcoRI site of the pLXSN retroviral vector (BD
Biosciences, San Jose, CA). Following sequence verification,
the TWIST expression construct or empty vector was trans-
fected into packaging Phoenix cells in serum-free DMEM/
F12 using Lipofectamine Plus reagent (Invitrogen) according
to the manufacturer’s recommendations. Twelve hours later,
the medium was replaced with medium containing 10% FBS.
Following an additional 24 hours of incubation, the medium
containing virus was collected, filtered through a PVDF filter,
and used for infection of SF767 cells in the presence of
4 mg/ml Polybrene (Sigma, St. Louis, MO). Selection of in-
fected cells was begun after 48 hours by culturing cells in
the presence of G418 (Sigma). Pools of G418-resistant
SF767 cells were collected and expanded, and endogenous
expression of TWIST protein was confirmed by Western
blot analyses. Cells overexpressing TWIST are designated
SF767Tw and empty vector controls SF767 LXSN.
TWIST Antibody
Twenty one amino acids (SSGGGSPQSTEELQTQRVMA)
specific for TWIST-1 protein near the loop region of the HLH
domain were chemically synthesized and conjugated with a
carrier, Keyhole limpet hemocyanin. After high-performance
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liquid chromatography (HPLC) analysis to determine Keyhole
limpet hemocyanin binding efficiency and peptide purification,
the protein antigen was injected into three rabbits for immu-
nization. The specificity of the peptide sequence for TWIST
and the lack of homology to other related bHLH or other pro-
teins were confirmed by performing a BLAST search of the
National Center for Biotechnology Information protein se-
quence database. Polyclonal serumwas prepared fromwhole
blood three times after primary and booster immunizations
(Beckman Research Institute, Duarte, CA). The specificity of
the antibody was tested in Western blots using cell lines with
undetectable, low, and high levels of TWIST mRNA and by
immunohistochemical analysis in tissue sections comparing
antibody staining patterns with patterns of TWIST message
detected by in situ hybridization.
Western Blot Analysis
Cells were harvested by scraping into cold PBS and lysed
in M-PER protein extraction reagent (Pierce, Rockford, IL)
supplementedwith protease inhibitors. Nuclear extracts were
prepared as previously described [28]. Protein concentra-
tions were determined using the BCA Protein Assay Reagent
Kit (Pierce). Proteins were separated in 4% to 15% Tris–HCl
gradient polyacrylamide SDS-PAGE gels (Bio-Rad, Hercu-
les, CA) and transferred by electroblotting to an Immun-Blot
PVDF membrane (Bio-Rad) in Tris–glycine buffer with 20%
methanol. Membranes were blocked with 5% nonfat dry milk
(NFDM) in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, and
0.02% Tween-20) for 30 minutes and incubated overnight
at 4jC with an antihuman TWIST rabbit polyclonal antibody
diluted 1:1000 in TBST containing 2% bovine serum albumin
(A3059 Fraction V; Sigma). After several washes with TBST,
membranes were incubated for 2 hours at room temperature
with horseradish peroxidase (HRP)–conjugated goat anti-
rabbit secondary antibodies (Pierce) diluted 1:5000 in TBST
containing 3% NFDM. After washes with TBST, antibody
binding was visualized on X-OMAT Blue XB-1 film (Kodak,
Rochester, NY) by chemiluminescence. For protein loading
control, the membranes were stripped and incubated in 5%
NFDM/TBST with either anti–b-actin goat polyclonal anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA), diluted
1:1000 for total proteins, or with INI1 (H-300) rabbit polyclonal
antibody (Santa Cruz Biotechnology), diluted 1:400 for nu-
clear proteins. After washes with TBST, membranes were
incubated in 3% NFDM/TBST for 45 minutes with secondary
antibodies diluted 1:5000: HRP-conjugated chicken antigoat
antibody (Santa Cruz Biotechnology) or HRP-conjugated
goat antirabbit antibody (Pierce).
RT-PCR and Southern Blot Analysis
cDNA was synthesized by RT using as a template
DNase I–treated total RNA that was extracted from cultured
cells and tissues using Trizol (Invitrogen). Controls for ge-
nomic DNA contamination were performed without reverse
transcriptase on matching samples. The sequences of
TWIST and GAPDH primers and of internal oligonucleotide
probes used for Southern blot analysis were either derived
from published sources, or designed using the MIT Primer
3 program (Table 1). PCR conditions were optimized to dem-
onstrate linear product formation at the cycle numbers used
for TWIST detection. Products were identified by Southern
hybridization with gene-specific internal oligonucleotide
probes. In addition, products from randomly selected RT-
PCR reactions for each gene were directly sequenced to
confirm their identity. Band density images of Southern hy-
bridizations or ethidium bromide–stained gels were quanti-
fied by using Image J shareware (Scion Corporation,
Frederick, MD; http://rsb.info.nih.gov/ij/) and normalized to
corresponding GAPDH readings for the same sample. Band
density was determined on a representative Southern hy-
bridization for tumor samples, and in triplicate for mouse
astrocyte experiments. Between-group differences were
tested for significance by using the Kruskal-Wallis test and
post hoc Mann–Whitney U tests.
In Situ Hybridization
Sense and antisense TWIST riboprobes were synthe-
sized by in vitro transcription from a 298-bp fragment from
the 3VUTR of human TWIST cloned into pBluescript SK+
(Stratagene, La Jolla, CA) using T7/T3 polymerases. Twelve-
micrometer sections previously fixed in 4% paraformalde-
hyde were freshly cut from tissue stored at 80jC. TWIST
in situ hybridization was performed using previously pub-
lished methods with minor modifications [26] (full protocol
available on request). The slides were either washed in water
and mounted in aqueous mounting media, or counterstained
in methyl green, dehydrated, cleared, and permanently
mounted. Adjacent sections were also stained with H&E.
Immunohistochemistry
Tumor or non-neoplastic samples were either fixed fresh
frozen with 4% paraformaldehyde or in formalin with paraffin
embedding and processed for H&E histology and immuno-
staining. Frozen samples were fixed in 4% paraformalde-
hyde, processed for histology, and stored frozen in OCT
compound (Sakura Finetek USA, Torrance, CA) at 80jC.
Both frozen and formalin-fixed paraffin-embedded samples
Table 1. RT-PCR Primer Sequences and Conditions for Human and Mouse Genes.
Gene Forward Sequence Reverse Sequence Internal Oligo TA Cycle # Product
Size
Human Twist GAGTCCGCAGTCTTACGAGG CTGCCCGTCTGGGAATCACT TTAGAAGAGCAAAATCCAAA(1)
CTACGCCTTCTCGGTCTGGA(2)
59 35 555
GAPDH ACGGATTTGGTCGTATTGGG TGATTTTGGAGGGATCTCGC ATGGCACCGTCAAGGCTGAG 60 28 231
Mouse Twist CACGCTGCCCTCGGACAA GGGACGCGGACATGGACC GCTGAGCAAGATTCAGACCC 60 30 197
GAPDH ATTGTCAGCAATGCATCCTGCA AGACAACCTGGTCCTCAGTGTA AACTTTGGCATTGTGGAAGG 59 25 412
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were sectioned at 6 mm thickness and processed for anti-
gen retrieval by heating in a microwave oven for 4 minutes
at 100% power, then 10 minutes at 10% power in 10 mM cit-
rate buffer, pH 6.0. Sections were allowed to cool to room
temperature for 30 minutes before staining. For TWIST immu-
nostaining, sections were incubated at 4jC with TWIST-
specific rabbit polyclonal antibody described above (1:800)
with detection of bound primary by the ABC method (Vectas-
tain, Vector Laboratories, Burlingame, CA) using DAB as
chromogen. Cell nuclei were visualized by hematoxylin coun-
terstaining. For immunoflourescent detection of TWIST pro-
tein in paraffin sections, the same protocol was followed, except
that TWIST primary antibody was detected with a donkey
CY3-conjugated antirabbit IgG (711-165-152, 1:400; Jackson
ImmunoResearch Laboratories, West Grove, PA). Double
immunofluorescence was performed by sequential staining
for TWIST as above, followed by incubation with mouse
monoclonal primary antibodies against either NeuN (MAB377,
1:1000; Chemicon, Temecula, CA), GFAP (G3893, 1:500;
Sigma), CD45 (M0701, 1:1000; Dako, Carpentiera, CA), or
CD68 (M8014, 1:200; Dako), followed by incubation with
FITC-conjugated antimouse IgG secondary antibodies (715-
095-151, 1:100; Jackson ImmunoResearch Laboratories).
Nuclei were counterstained with DAPI (D-1306; Molecular
Probes, Eugene, OR), and coverslips were mounted with
fluoromount (SouthernBiotech, Birmingham, AL) and light-
protected prior to visualization with fluorescent microscopy
(Zeiss Axioplan 2, Carl Zeiss USA, Thornwood, NY). Con-
trols omitting primary antibody or using an isotype IgG were
performed on all samples. Digitally captured images (Slide-
book software; III) were analyzed for double-labeled TWIST
immunopositive cells using Image J software (Scion Corpo-
ration) by counting at least four 20 fields from two separate
brain samples that included both gray and white matter.
Cell Growth and Saturation Density
For cell growth, 1 105 cells in DMEM/F12 supplemented
with 10% FBS were plated in 60-mm plates in triplicate. Cells
were counted everyday for 4 days using a Coulter counter
(Beckman-Coulter, Fullerton, CA). For saturation density
assays, 2  105 cells were seeded in six-well plates in trip-
licate. Cells were counted every second day for 7 days.
Matrigel Invasion Assays
The invasion assay was performed using 24-well BD
BioCoat Matrigel invasion chambers (BD Biosciences) and
QCM cell invasion chambers (Chemicon). Chambers consist
of a cell culture insert with an 8-mm pore size membrane
coated with a thin layer of BD Matrigel Matrix or Chemicon
ECMatrix. SF767 LXSN or SF767Tw cells were harvested,
resuspended in a serum-free DMEM, and loaded into the
insert (BD Biosciences: 5  104 cells/500 ml; Chemicon: 3 
105 cells/300 ml) according to the manufacturer’s recom-
mendations. DMEM/F-12 with 10% FBS was then added to
the lower chamber (750 ml for BD Biosciences; 500 ml for
Chemicon). Cells were incubated at 37jC for 70 hours (BD
Biosciences) or 48 hours (Chemicon) before noninvading
cells and matrix gel from the insert were gently removed with
a cotton swab. For both assays, invasive cells that pene-
trated through pores and migrated to the underside of the
membrane were stained with the staining solution provided
by the manufacturer (Chemicon) for 20 minutes and photo-
graphed. For quantitation in both assays, stained cells were
dissolved in 200 ml of 10% acetic acid and 100 ml was used for
colorimetric reading of OD at 560 nm.
In Vitro p53-Deficient Model of Astrocyte Transformation
Mouse astrocytes were cultured from postnatal day 1mice
from wild-type (p53+/+), p53 hemizygous (p53+/), or p53
homozygous knockout (p53/) animals as previously de-
scribed [22,29]. Frozen cell pellets of p53/ astrocytes and
selected samples of p53+/, p53+/+, and p53/ astrocytes
harvested at varying passage numbers were used for the
isolation of total RNA and RT-PCR for TWIST mRNA.
Results
TWIST mRNA and Protein Are Frequently Expressed
in Glioma Cell Lines
Examination of rat C6 glioma cells for class B bHLH
genes by a degenerate RT-PCR cloning strategy revealed
the presence of TWISTmRNA. TWIST expression in C6 was
confirmed by Northern blot analysis (Figure 1A), suggesting
that TWIST may play a role in glial tumorigenesis. To eval-
uate the relevance of our finding in human gliomas, we
examined TWIST expression by Northern blot analysis in
11 human cell lines, including six gliomas. Five of six glioma
lines expressed variable levels of the documented major
1.4-kb TWIST transcript, together with minor transcripts at
2.2 and 3.6 kb (Figure 1A) [30,31]. TWIST message was
also detected in human neuroblastoma and medulloblas-
toma, but not in colon, breast, or SCLC cell lines examined.
The findings in Northern blot analysis were confirmed and
expanded on using RT-PCR to assay TWIST expression in a
larger panel of 21 human tumor cell lines including those
examined by Northern blot analysis. As shown in Figure 1B,
11 of 12 glioblastoma (i.e., grade IV) cell lines expressed
TWIST; RT-PCR confirmed the lack of TWIST message
revealed by Northern blot analysis of UW455. TWIST was
also detected by RT-PCR in cell lines derived from neuro-
blastoma and medulloblastoma—primitive neuroectodermal
tumors that arise in the peripheral nervous system and
CNS, respectively [32,33]. To our knowledge, this is the first
demonstration of TWIST expression in medulloblastoma
cell lines, whereas expression of TWIST in neuroblastoma
has recently been described in association with N-myc am-
plification [12]. As observed in the Northern blot analysis
(Figure 1A), TWIST was not detected in the two colorectal,
small cell lung, and breast carcinoma–derived cell lines ana-
lyzed byRT-PCR.Our results demonstrate thatTWISTmRNA
is frequently expressed in human glioblastoma–derived cell
lines and indicate that TWIST expression is a hallmark of
glial and nonglial tumors of neuroectodermal lineage.
To analyze TWIST protein in cell lines, first we confirmed
the specificity of polyclonal anti-TWIST antibody usingSF767
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cells transduced with TWIST-expressing retrovirus. We
chose SF767 cells because they express low basal levels
of message by Northern blot analysis (Figure 1A). UW455
cells, which lack detectable TWIST message (Figure 1A),
served as a negative control. Figure 1C shows that in 30 mg
of whole cell extracts of glioma cells overexpressing TWIST
(SF767Tw), the antibody detected a single protein band of
approximately 26 kDa. The 26-kDa molecular weight is
consistent with the previously reported size for the TWIST
protein [30]. Then we tested endogenous levels of TWIST
expression in glioblastoma cell lines using cell nuclear ex-
tracts. Because endogenous levels of TWIST protein are low,
we reduced the amount of nuclear proteins from positive
control cells (SF767Tw) loaded on the gel to 10 mg, whereas
50 mg of nuclear extracts from other cell lines was loaded
alongside (Figure 1D). Levels of endogenous TWIST protein
of the same molecular weight were detected and correlated
well with Northern blot analysis of RNA from the same cell
lines. Therefore, we conclude that the polyclonal TWIST
antibody interacts specifically with TWIST protein, and that
TWIST protein present in human glioma cell lines reflects
steady-state levels of TWIST mRNA.
TWIST mRNA Content Is Associated with Grade
in Human Gliomas
We examined 10 grade II, 6 grade III, and 12 grade IV
gliomas of differing histologies to determine if TWIST mRNA
is expressed in vivo in human gliomas. Nineteen tumors
were newly operated, whereas nine had recurred after either
previous surgery (n = 1), surgery followed by radiotherapy
(n = 3), or surgery followed by radiotherapy and chemo-
therapy (n = 5). Using semiquantitative RT-PCR, TWIST
mRNA was detected in 89% (25 of 28) of gliomas (Figure 2,
A and B). TWIST abundance did not differ discernibly be-
tween newly operated and recurrent tumors (Figure 2A). As
shown in Figure 2, B and C, mean TWIST transcript band
Figure 1. Expression of TWIST mRNA and protein in rodent glioma and human glioblastoma cell lines. (A) Northern blot analysis showing the expression of
TWIST in rat C6 glioma cells (far left lane), confirming the results of a degenerate RT-PCR screen for class B bHLH genes. TWISTmRNA expression was detected
in five of six human glioma cell lines (A172, T98G, SNB19, UW455, UW18, and SF767), as well as in lines derived from a neuroblastoma (SKNMC) and a
medulloblastoma (D283). Lines derived from colon (SW480), breast (MDA453), and small cell lung cancer (H82) had no detectable expression. The gel stained
with ethidium bromide (lower panel) demonstrates equivalent loading and integrity of total RNA. (B) Southern hybridization of TWIST-specific probes to RT-PCR
products from a larger panel of human tumor cell lines. Blots of GAPDH controls show that comparable amounts of total RNA were analyzed for each sample.
Differential levels of TWIST expression were detected in 11 of 12 human gliomas and in two neuoblastomas and one medulloblastoma, whereas no detectable
expression was noted in non-neural tumors. TWIST mRNA was not detected by RT-PCR or by Northern blot analysis in the glioblastoma line, UW455, or in the
non-neural cell lines examined. (C) Western blot analysis of 30 g of whole cell lysates of UW455 and SF767, transfected either with an empty expression vector
(LXSN) or a TWIST overexpression construct (Tw), demonstrates the presence of a band at the expected molecular mass of 26 kDa. UW455, which lacks
detectable TWIST mRNA and SF767LXSN with low basal message levels, shows no detectable protein. (D) Nuclear extracts of the SF767LXSN, SNB19LXSN,
and T98G cell lines (50 g each) demonstrate endogenous expression of a 26-kDa TWIST protein comparable to that detected in nuclear extracts from SF767Tw
(10 g) at levels commensurate with mRNA levels (panel A). The nuclear protein, INI1, is used to compare the levels of nuclear-specific protein loaded from
each preparation.
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intensity, expressed as a percentage of that for GAPDH,
was approximately three-fold greater in grade IV than in
grade II tumors (29.6 ± 24.5 vs 10.0 ± 8.9; P = .015) and in
combined grade II and III tumors (10.5 ± 7.4; P = .01). Mean
normalized TWIST expression in grade III gliomas (11.2 ±
4.5) was markedly less than grade IV, but the difference was
not statistically significant (P = .09). These results indicate
that overall TWIST mRNA levels reflect degree of malig-
nancy (Figure 2C), a conclusion supported by the observa-
tion that the three tumors with no detectable TWIST were
grade II. Nonetheless, TWIST levels varied considerably be-
tween and within diagnostic subtypes, as evidenced by the
~70-fold range of normalized TWIST content for grade IV
(Figure 2B). Our data indicate that TWIST mRNA expres-
sion commonly accompanies glial tumorigenesis, and that
higher expression is associated with grade IV tumors.
TWIST Expression Is Localized to Tumor Cells
To elucidate the intratumoral localization of TWISTmRNA
in gliomas, we examined expression by in situ hybridization
in two grade II, one grade III, and three grade IV gliomas;
representative results are shown in Figure 3. Importantly,
TWIST-specific hybridization reflected TWIST mRNA content
detected by RT-PCR as evidenced by greater hybridization
associated with increasing tumor grade. Thus, a low-grade
glioma with barely detectable TWIST expression by RT-PCR
(sample 7; Figure 2A) showed only faintly discernible hybrid-
ization (Figure 3E ), whereas two grade IV gliomas with high
levels of TWIST mRNA (samples 24 and 28 in Figure 2A)
showed intense hybridization in a majority of cells (Figure 3,
F and G). Notably, the grade IV tumors displayed in situ
hybridization signal intensity comparable to that of rhabdo-
myosarcoma (Figure 3H ), a highly malignant mesenchymal
neoplasm known to overexpress TWIST [10]. Although the
overall intensity of TWIST hybridization corresponded to
tumor grade, hybridization intensity varied markedly among
cells within a glioma (Figure 3, E–H ). The variation in TWIST
message abundance in these samples was corroborated
by immunostaining of the same specimens (Figure 3, I–L).
Although only sparse immunoreactivity was detected in the
low-grade tumor (Figure 3I ), markedly elevated TWIST im-
munoreactivity was demonstrated in tumor nuclei of samples
from the grade IV gliomas (Figure 3, J and K ) and rhabdo-
myosarcomas (Figure 3L).
TWIST Expression and Malignant Progression
The increased levels of mRNA expression in grade IV
tumors suggest that elevation of TWIST accompanies the
malignant progression of gliomas. To further characterize
the association of TWIST with malignant progression in
gliomas, we examined changes in mRNA and protein con-
tent that accompanied the recurrence of a low-grade oligo-
dendroglioma as a grade IV glioblastoma in the same patient.
As shown in Figure 4, TWIST protein content detected by
immunostaining (Figure 4,A andB) and TWISTmRNA abun-
dance (Figure 4D) was markedly increased in the high-grade
recurrence. Importantly, the increase in TWIST protein con-
tent colocalized with malignant histologic hallmarks (in-
creased cellularity, nuclear and cellular atypia, endothelial
proliferation, and necrosis) in the recurrent tumor (Figure 4C).
Figure 2. TWIST expression in human gliomas. The abundance of mRNA was analyzed by Southern hybridization of TWIST- and GAPDH-specific probes to RT-
PCR products. (A) Glial tumors, grouped by grade, include grade II fibrillary astrocytomas (1–3), oligodendroglioma (4–9), and mixed oligoastrocytoma (10);
grade III anaplastic mixed oligoastrocytomas (11–13) and anaplastic astrocytoma (14–16); and grade IV glioblastoma (17–26) and gliosarcoma (27 and 28). The
nine tumors recurrent after prior treatment are indicated by a caret beneath the corresponding lane. No statistical difference in gene expression levels between
primary or recurrent samples was noted (data not shown). Representative RT-PCR controls without RT or cDNA are shown at the far right. (B) Histogram of relative
TWIST expression for gliomas, grouped by grade. The signal density of TWIST is expressed as a percentage of the corresponding GAPDH signal. (C) Mean
relative TWIST expression with standard errors of the mean by glioma grade. Significant differences (P V .05) indicated by asterisks were demonstrated between
grades II and IV (**) and combined grade II plus grade III and IV tumors (*).
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Areas histologically similar to the original low-grade glioma
either lacked or exhibited low levels of TWIST protein (data
not shown). This correlation between the presence of TWIST
and anaplastic histologic features suggests that, in this case,
elevated levels of TWIST protein expression accompanied
malignant glial progression. This observation supports a role
for TWIST in malignant progression.
Elevation of TWIST mRNA Precedes In Vitro
Transformation of Mouse Astrocytes
To gain additional insights into the association of TWIST
with glial tumorigenesis, we analyzed its expression in an
in vitro model of astrocyte transformation. Cultured neo-
natal mouse astrocytes hemizygous for p53 spontaneously
undergo a well-defined sequence of genetic and physio-
logical changes culminating in malignant transformation
[22–34]. We examined by RT-PCR the abundance of TWIST
mRNA in serially passaged p53+/ mouse astrocytes de-
rived from postnatal day 1 animals. As shown in Figure 5,
TWIST mRNA content normalized to GAPDH was approxi-
mately 10- and 7-fold greater in p53+/ than in p53+/+ cells at
passages 1 and 4, respectively. By passage 8, when these
cells are known to lose the remaining wild-type copy of
p53 and develop aneuploidy [22], TWIST expression in-
creased an additional 30%. Similar changes in TWIST
expression were observed in homozygous p53/ astro-
cytes (data not shown). TWIST content remained elevated
through passage 50, at which time the cells displayed serum-
independent growth and formed tumors in vivo [22]. In
contrast, TWIST abundance was unchanged in wild-type
astrocytes through passage 4, the approximate limit of their
proliferative potential in vitro, and was comparable to the
level in adult wild-type mouse brain. Wild-type astrocytes
senesce by passage 6 or 7 and additional comparison of
TWIST levels with p53-deficient astrocytes at subsequent
serial passage numbers are not possible. Our data suggest
that elevated TWIST expression accompanies loss of p53
function and the resulting increase in genomic instability
associated with malignant transformation.
Overexpression of TWIST Promotes Glioma Cell Invasion
To delineate potential roles for TWIST in glioma biology,
we examined the effect of TWIST overexpression in SF767
(SF767Tw) on cell proliferation, saturation density, and in-
vasion through an artificial basement membrane matrix. As
shown in Figure 6A, SF767Tw cells displayed slightly slower
Figure 3. TWIST expression patterns in low-grade and high-grade gliomas by in situ hybridization and immunostaining. H&E histology (A–D), TWIST in situ
hybridization (E–H), and immunostaining (I–L) are shown from adjacent sections of sample 7, a grade II glioma with low levels of TWIST by RT-PCR (A, E, and I);
sample 24, a grade IV glioblastoma (B, F, and J); sample 28, a grade IV gliosarcoma (C, G, and K) with strong TWIST expression; and a rhabdomyosarcoma (D, H,
and L), previously reported to express TWIST [10]. H&E and in situ hybridization photomicrographs were taken with 20 objective, whereas iummunostained images
were taken with a 40 objective. Sense control hybridization reactions for each sample are shown as insets in the right lower hand corner (E–H). In situ hybridization
sections were counterstained with methyl green to facilitate visualization of tissue architecture. Immunostaining demonstrates occasional faint staining in the low-grade
sample (I), whereas abundant pronounced nuclear staining is present in all of the high-grade tumors (J–L). Nuclear staining is not apparent in isotype IHC controls
(lower right corner insets), indicating the specificity of the antibody. (The 50-m scale bar in (A) applies to (A)– (H), and the 25-m scale bar in (I) applies to (I)– (L).)
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growth rates that led to reduced saturation density (Figure 6B)
compared to SF767 containing vector alone. Interestingly,
suppression of TWIST expression in 4T1 mouse mammary
carcinoma cells resulted in a small increase in growth rate
[15]. TWIST overexpression has been reported to alter cell
morphology in MDCK kidney epithelial cells, immortalized
human mammary epithelial cells [15], and osteosarcoma cells
[30], but similarmorphologic changes inTWIST-overexpressing
SF767 cells were not observed (data not shown). The report
that TWIST expression is necessary for mammary carcinoma
metastasis in rodents and is elevated in invasive human breast-
carcinomas led us to hypothesize that TWIST promotes inva-
sionbyhumangliomas. Inaccordwithourhypothesis,SF767Tw
displayedgreater infiltration through twodifferentMatrigel extra-
cellular matrices than control cells (Figure 6, C and D). These
findings suggest that, by promoting invasiveness, TWIST con-
tributes to a hallmark characteristic of human gliomas.
TWIST Is Expressed in Normal Fetal and Adult
Human Brain
Expression of TWIST in developing or adult mamma-
lian brain has not been unambiguously delineated [31,35].
To better clarify the potential role of TWIST expression in
gliomagenesis, we examined TWIST mRNA content in
human developing and mature brain by RT-PCR. As shown
in Figure 7A, abundant levels of TWIST were detected in all
samples of embryonic and fetal brain that ranged from day
52/53 to day 132 postconception, suggesting that TWIST
participates early in the development of the human brain.
Notably, the level of expression in developing brain was
comparable to that in mesenchyme-derived human embry-
onic bone (Figure 7A). TWIST was also detected by RT-PCR
at levels comparable to that of adult temporalis muscle in
seven non-neoplastic brain samples obtained from adults
operated either for epilepsy (four males and one female,
36–46 years old) or benign skull base tumors (two males,
32 and 48 years old). TWISTmessage was detected by in situ
hybridization (data not shown) in adult muscle in satellite cells,
consistent with previous observations that TWIST is ex-
pressed in adult myoblasts [36]. In brain samples that were
macroscopically dissected from fresh brain tissue, TWIST
expression was exclusively detected in the gray matter in
three of four specimens with only trace expression in one of
four white matter specimens. Representative results are
shown in Figure 7A. In situ hybridization performed on two
brain specimens corroborated these findings and revealed
pronounced staining of cells with morphologic characteristics
of neurons (Figure 7, B and C), with rare staining evident in
white matter, which did not localize to morphologically identi-
fiable cell types (Figure 7, F andG). Immunostaining of normal
graymatter (Figure 7D) and white matter (Figure 7H) or gray–
white junction (Figure 7,E and I ) samples further corroborated
the findings of RT-PCR and in situ hybridization, which
Figure 5. TWIST mRNA abundance is elevated by p53 deficiency in mouse
astrocytes. (A) Comparison of TWIST mRNA detected by Southern hybrid-
ization of RT-PCR reaction products from cultured p53 wild-type (+/+) and
hemizygous (+/) astrocyte cultures derived from neonatal mice. Also shown
are levels in normal adult mouse brain (NAB) and a control lacking RT. (B)
Density of TWIST mRNA signal normalized to that of GAPDH of samples
shown in (A). Values are the mean ± SD of three independent determina-
tions. The appearance of features accompanying malignant transformation at
specific passage numbers is indicated as follows: DNA ploidy abnormalities
(*), serum-independent growth, and tumor formation in nude mice (^). The
marked increase of TWIST expression in p53+/ astrocytes relative to normal
brain and wild-type astrocytes at passages 1 and 4 is maintained through
serial passages coinciding with progressive acquisition of malignant phe-
notype in vitro, including complete malignant transformation (growth of solid
tumors in vivo) by passage 50.
Figure 4. Increased TWIST protein and mRNA content accompanies malig-
nant progression. Immunostaining revealed increased abundance of TWIST
protein accompanying the recurrence of a grade II oligodendroglioma (A) to a
grade IV glioblastoma (B). The recurrent tumor demonstrates increased cellu-
larity characteristic of glioblastoma, together with pronounced TWIST immuno-
positivity in tumor cell nuclei. High levels of TWIST protein (C) were particularly
evident in areas of the recurrent tumor with malignant histologic features of
increased cellularity, necrosis (asterisk), and microvascular proliferation
(arrow). In accord with the elevated level of TWIST protein evident by immuno-
staining, the recurrent sample demonstrates increased abundance of TWIST
mRNA by RT-PCR (D). (The 40-m scale bar in (A) applies to (A) – (C).)
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suggested that in normal brain, TWIST protein and mRNA are
almost exclusively localized to neurons in gray matter.
TWIST Expression in Adult Brain Localizes to Neurons
The identity of TWIST-expressing cells in the normal
brain is of central importance to establishing the impor-
tance of TWIST in human gliomagenesis. To confirm the
results of in situ hybridization, which suggested that TWIST
mRNA expression is confined to neurons, we performed
double-label immunofluorescent staining experiments
using two different normal brain samples and found that of
315 TWIST-expressing cells, 305 (or 97%) coexpressed the
neuronal marker NeuN (Figure 8, A–C). Conversely, we
were not able to unambiguously identify any TWIST-
expressing cells that coexpressed GFAP (Figure 8, D–F ),
indicating that TWIST protein expression is almost exclu-
sively restricted to neuronal cells in the non-neoplastic
human brain. TWIST protein was not detectable in white
matter (Figures 7, H and I and 8F ), in agreement with in situ
hybridization and RT-PCR results. Our analysis also indi-
cated that TWIST is not expressed in lymphocytes or micro-
glia (data not shown). To our knowledge, these results are
the first evidence of expression of TWISTmRNA and protein
in human developing brain and mature neurons. Our findings
suggest that TWIST participates in the development of the
CNS, and may have as yet undetermined roles in the biology
of mature neurons. The restriction of expression to neurons
indicates that TWIST in human glioma cells is a conse-
quence of oncogenic transformation, rather than persistent
expression of a gene present in normal glia.
Discussion
Primary brain tumors remain among the most lethal of
human cancers despite more than three decades of inten-
sive effort to develop more effective surgical techniques, and
radiation-based and chemotherapy-based adjuvant thera-
pies [37,38]. The persistent dismal prognosis for the most
common brain malignancies in adults and children has
stimulated the search for novel therapies. The recognition
that neural precursor cells in the adult brain are the likely
targets for malignant transformation [39–41] has stimulated
Figure 6. Overexpression of TWIST promotes invasion but not cell proliferation in SF767 glioma cells. (A) The impact of TWIST overexpression on cell growth
rate in culture was examined by plating 1  105 SF767Tw or SF767 LXSN vector control cells in 60-mm plates in triplicate. Cells were trypsinized and counted each
day for 4 days using a Coulter counter, and the mean of three wells from each time point is shown. (B) TWIST effects on cell saturation density were assayed by
plating 2  105 SF767Tw or SF767 LXSN vector control cells in six-well plates in triplicate. Triplicate wells were trypsinized and counted every second day for
7 days using a Coulter counter and plotted. Calculated standard errors were small and cannot be visualized at this scale. (C, D) Invasion through two extracellular
matrices is increased by overexpression of TWIST in SF767 assayed by two separate invasion assays (C, Chemicon; D, BD Biosciences). Data were analyzed
after 70 hours for BD Biosciences and 48 hours for the Chemicon assay. Photomicrographs of stained cells on the undersurface of matrix-coated 8-m pore size
filter demonstrate differential invasion of SF767 LXSN and SF767 TW cells. Cells from triplicate assays were stained and quantified by colorimetric reading at OD
of 560 nm. Invasion by SF767TW was calculated as a percentage of the SF767 LXSN vector control values. Data shown are mean ± SE.
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investigation of the recapitulation of developmental gene
expression during glial tumorigenesis in the hope of un-
covering new targets for therapeutic intervention. Here we
show that human gliomas frequently express TWIST, an
essential regulator of mesodermal development [42]. Ex-
pression was observed in all major glioma diagnoses as well
as in medulloblastoma-derived and neuroblastoma-derived
cell lines, indicating that TWIST participates in the genesis of
a wide range of neuroectodermal tumors. Expression was
also observed in embryonic and fetal brain and, unexpectedly,
in mature neurons, suggesting that TWIST promotes glioma-
genesis by the aberrant activation of a previously unrecog-
nized pathway(s) normally involved in the development and
function of the human CNS. Importantly, the demonstration
that TWIST promotes glioma cell invasion supports functions
for TWIST in human gliomas similar to those demonstrated
for other non-neural cancers [15].
Current evidence indicates that TWIST functions as an
oncogene by enhancing cell survival through inhibition of
p53-mediated apoptosis [10], preventing growth arrest that
accompanies developmental maturation [36,43–46] and
promotion of tumor cell invasiveness [15]. The ability of
TWIST to foster cell survival would enhance tumor progres-
sion by increasing resistance to cytotoxic therapies as well
as endogenous cytotoxic stresses such as reactive oxygen
free radicals generated in association with increased cellu-
lar proliferation [47,48]. Indeed, elevated levels of TWIST in
other transformed or normal cells are associated with resis-
tance or reduced sensitivity to cytotoxic drugs [14,35]. The
antiapoptotic function of TWIST may be a primary defense
against endogenous insults in the sizeable minority of glio-
mas that possess functional p53 and may also provide a
secondary or complementary mechanism that promotes
survival in the majority of gliomas in which p53 function is
Figure 7. Expression of TWIST in human developing and adult brain. (A) Southern hybridization of RT-PCR reactions from embryonic, fetal, and adult tissues
including control bone tissue (79 days) known to express TWIST and a panel of embryonic and fetal brain (Br) samples from 52/3 to 132 days showing TWIST
expression throughout this developmental time frame. TWIST expression in temporalis muscle (Ad Muscle) and rhabdomyosarcoma (Rhabdo) is consistent with
the known expression of TWIST in adult muscle progenitor cells [36] and the mesenchymal-derived tumor [10]. TWIST is differentially expressed in adult brain, with
expression detected in gray matter (GM) but at low or undetectable levels in white matter (WM). (B and F) H&E histologic sections (20) of normal gray matter
(B) and white matter (F) are compared with ISH (20) for TWIST expression from adjacent sections of gray (C) and white matter (G). Insets in the right lower corner
(C and G) are sense controls. TWIST IHC (20) for normal gray matter (D) and white (H) matter corresponds to expression patterns by ISH. Inset: 40 images in
(D) and (H) demonstrate nuclear staining pattern in cells with neuronal morphology. (E and I) The demarcation of TWIST protein expression between normal gray
and white matter is demonstrated in low-power (10) photomicrographs of a normal brain sample with a diagonally oriented junction between gray (upper right)
and white matter (lower left) by H&E histology (E) and TWIST IHC (I). These data indicate that TWISTmessage and protein are almost exclusively detected in gray
matter. (The 50-m scale bar in (B) applies to (B) – (D) and (F) – (H); the 25-m scale bar in the (D) inset applies to insets of (D) and (H); and the 100-m scale
bar in (E) applies to (E) and (I).)
TWIST Expression in Gliomas Elias et al. 833
Neoplasia . Vol. 7, No. 9, 2005
suppressed or inactivated [49–51]. In accord with this hy-
pothesis is the observation that coexpression of c-myc and
TWIST inhibits p53-mediated apoptosis and promotes trans-
formation in embryonic mouse fibroblasts [10].
Recently, it has been shown in neuroblastoma that onco-
genic cooperation between TWIST and N-myc promotes
malignant transformation and cell survival in response to
cytotoxic stress by inhibiting p53 function [12]. In genetically
engineered mice, c-myc overexpression targeted to GFAP-
expressing cells produces tumors analogous to human glio-
blastoma [52]. Notably, grade III and IV human gliomas
demonstrate marked elevations of c-myc expression rela-
tive to normal brain and low-grade tumors [53]. Thus, these
data and our demonstration of TWIST mRNA and protein
in human gliomas suggest that, similar to neuroblastoma,
oncogenic cooperation between TWIST and other onco-
genes such as c-myc may contribute to glioma treatment
resistance by promoting cell survival, in part, through abro-
gation of p53-mediated apoptosis.
Another function of TWIST relevant to human gliomas
is promotion of EMT. In epithelial-derived solid tumors, EMT
is a critical component of the metastatic cascade whereby
transformed epithelial cells lose normal cell–cell interaction
and adopt a mesenchymal phenotype characterized by
invasion through basement membrane [54]. TWIST expres-
sion has been associated with EMT in gastric carcinoma [13]
and is essential in mouse mammary carcinoma models for
EMT and metastasis, in part, by promoting cell motility [15].
Of note, elevated levels of TWIST are found in the most
invasive types of breast carcinoma cell lines and tumors
[15]. In the present study, the highest levels of TWIST ex-
pression were present in grade IV tumors and overexpres-
sion of TWIST promoted glioma invasion in vitro. Tumor cell
migration and invasion into surrounding brain are two fea-
tures of human gliomas that increase with tumor grade.
Thus, the promotion of invasion appears to be a function of
TWIST shared by both breast and glial cancers. The limi-
tations to surgical resection and effective delivery of sys-
temic and local therapies posed by the diffusely invasive
behavior of glioma tumor cells underscore the importance of
characterizing TWIST function in primary brain tumors.
Although direct evidence is currently lacking, TWIST func-
tion may also be linked to the activation of receptor tyrosine
kinases (RTKs) overexpressed in human gliomas that con-
trol cell survival and invasion. In other cell types, TWIST
expression is elevated by the RTKs IGFR1 and c-met, whose
ligands are IGF-1 and HGF, respectively [35,36]. Antisense-
mediated suppression of TWIST reduces the ability of IGF-1
to rescue NIH 3T3 fibroblasts from etoposide-mediated cell
death [35]. In human gliomas, both RTKs are overexpressed
Figure 8. TWIST is expressed almost exclusively in neurons of the adult brain. (A–C) Photomicrographs of indirect immunofluorescent staining with TWIST
antibody (Cy3) of normal human gray matter (A), the neuronal marker NeuN (FITC) (B), and the merged image (C) show colocalization of TWIST with NeuN in
almost every TWIST immunoreactive cell (arrow). Sections were also stained with DAPI and indicate that NeuN-negative cells do not express TWIST. (D–F) A
section of normal human brain containing gray and white matter stained for TWIST (Cy3) (D) and GFAP (FITC) (E), and the merged image with DAPI nuclear stain
(F) demonstrate that TWIST is found exclusively in gray matter and that TWIST-expressing nuclei (arrowhead) do not colocalize with GFAP-immunopositive cells
(arrow). The junction between gray and white matter is indicated by the dotted line. These results demonstrate that TWIST is almost exclusively found in neurons.
(The 50-m scale bar in (A) applies to (A) – (F).)
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and their signaling pathways are activated, in direct corre-
lation with tumor grade [35,55–58]. Importantly, activation of
the IGF-1/IGFR1 and HGF/c-met signaling pathways pro-
motes survival of glioma cells exposed to cytotoxic agents
[58–60] and enhances tumor cell migration and invasive-
ness [61–64]. Of particular interest, IGF-1/IGFR1 and HGF/
c-met signaling activates AKT [58,65], which mediates in-
creased resistance to apoptosis demonstrated by migratory
glioma cells [66]. These observations and the demonstrated
role for TWIST in regulating glioma cell invasion and sur-
vival in other cancers warrant further investigation of TWIST
interactions with RTK signaling and activation of AKT.
Our examination of embryonic, fetal, and mature human
brain, the most comprehensive to date, unambiguously indi-
cates that TWIST expression is associated with early devel-
opment of the human CNS. Conceivably, the antiapoptotic
and invasion-promoting activities of TWIST facilitate the
migration and expansion of neural progenitor populations
during CNS development. We note that our findings stand
in contrast to an earlier report of an absence of TWIST in
human fetal astrocytes and adult human brain by Northern
blot analysis [31]. Our analyses, however, support the ex-
pression of TWIST in fetal brain, and in neurons in adult
brain. The low levels of TWIST expression detected inmouse
neonatal astrocytes and adult human white matter, and the
relative differences in sensitivity between Northern blot
analysis and RT-PCR analysis may account for these dif-
ferences. TWIST promotes resistance to p53-mediated
apoptosis and cell proliferation, and inhibits differentiation
in experimental models [10,46]. Accordingly, in normal tis-
sues, its expression has predominately been localized to
proliferative and immature cells ofmesodermal origin [67–69],
although expression in some mature cell types has been de-
scribed [31,67]. Thus, finding TWIST mRNA in mature neu-
rons was unexpected. It is conceivable that the antiapoptotic
function of TWIST operates in quiescent neurons as well as
in proliferating cells. Neuronal activity is associated with high
rates of oxygen utilization that elevate the rate of endogenous
generation of reactive oxygen free radicals. TWIST would
likely promote neuronal survival by inhibiting the induction of
apoptosis by these damaging agents.
Our results, together with previous findings in other
human tumors, suggest the following model in which TWIST,
by promoting survival, malignant progression, and invasion,
facilitates glial tumorigenesis and glioma clinical behavior.
TWIST in low-grade gliomas may promote resistance to
endogenous and exogenous cytotoxic stress that would
otherwise lead to apoptotic cell death. By promoting sur-
vival, TWIST could facilitate the accumulation and propa-
gation of mutations that are associated with glial tumor
progression. TWIST could then interact synergistically with
mutation-induced oncogene activation, in similar fashion to
the oncogenic cooperation observed between N-myc and
TWIST in neuroblastoma [12], to promote and maintain a
more malignant phenotype. Candidate target oncogenes for
interaction with TWIST include RTKs as well as c-myc. This
scenario outlines the potential functions of TWIST related to
the genesis of low-grade gliomas and their malignant pro-
gression to ‘‘secondary’’ glioblastomas. In the case of ‘‘pri-
mary’’ glioblastoma, which infrequently demonstrates p53
mutations [70], TWIST may function alone or in combination
with other oncogenes to promote tumor growth and treat-
ment resistance, in part by inhibiting p53-mediated apop-
tosis. Importantly, TWIST may promote glioma cell invasion
of surrounding normal brain, a major factor contributing to the
dismal prognosis for glial tumors. The mechanisms by which
TWIST contributes to gliomagenesis and glioma physiology
and normal CNS development remain to be more fully char-
acterized. Elucidating the pathways that elicit aberrant
TWIST expression in gliomas, as well as characterizing the
effectors of TWIST activity, are likely to provide new insights
into the genesis of gliomas and to identify new targets for
therapeutic intervention.
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